Mixed Monoclonal Antibody Cocktail for Cancer Immunotherapy from Mexico
This product is a blend of multiple monoclonal antibodies (e.g., pembrolizumab and nivolumab derivatives) designed for immunotherapy treatment of solid tumors. It falls under HTS 3002.14.00.90 as mixed immunological products not in measured doses or retail packaging, per chapter notes defining immunological products as peptides/proteins regulating immunological processes.
Duty Rate — Mexico → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Obtain FDA biologics license application (BLA) approval prior to import; provide lot-specific certificates of analysis
• Declare as mixed immunological product; avoid retail packaging to stay in 3002.14, include biotech process details